Email this article 
Press Release
- Issue: Vol 13, No 4 (2018)
- Pages: 104-106
- Section: PRESS RELEASE
- Published: 03.12.2018
- URL: https://oncohematology.abvpress.ru/ongm/article/view/326
- ID: 326
Cite item
Full Text
Abstract
.
References
- Seymour J. MURANO trial establishes feasibility of time-limited venetoclax-rituximab (VenR) combination therapy in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Presented at the 2018 American Society of Hematology Annual Meeting & Exposition: December 1, 2018; San Diego.
- Instructions for medical use of the drug Venclexta. Available at: https://grls.rosminzdrav.ru/GRLS.aspx (date of the application: 05.12.2018) (In Russ.).
- VENCLYXTO Summary of Product Characteristics EMA. Available at: https://www.ema.europa.eu/documents/product-information/venclyxtoepar-product-information_en.pdf (05.12.2018).
- Hallek M., Cheson B.D., Catovsky D. et al. Guidelines for diagnosis, indications for treatment, response assessment and supportive management of chronic lymphocytic leukemia. Blood 2018;131(25):2745–60. doi: 10.1182/blood-2017-09-806398. PMID: 29540348.
- Seymour J.F., Kipps T.J., Eichhorst B. et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018; 378(12):1107–20. doi: 10.1056/NEJMoa1713976. PMID: 29562156.
Supplementary files
